Wagoner M P, Yang Y, McDuffie J E, Klapczynski M, Buck W, Cheatham L, Eisinger D, Sace F, Lynch K M, Sonee M, Ma J-Y, Chen Y, Marshall K, Damour M, Stephen L, Dragan Y P, Fikes J, Snook S, Kinter L B
Takeda Pharmaceuticals, 35 Landsdowne St., Cambridge, MA, 02139. United States.
Abbvie, North Chicago, IL. United States.
Curr Top Med Chem. 2017;17(24):2767-2780. doi: 10.2174/1568026617666170713172331.
Urinary protein biomarkers and metabolomic markers have been leveraged to detect acute Drug Induced Kidney Injury (DIKI) in rats; however, the utility of these indicators to enable early detection of DIKI in canine models has not been well documented. Therefore, we evaluated temporal changes in biomarkers and metabolites in urine from male and female beagle dogs. Gentamicin- induced kidney lesions in male dogs were characterized by moderate to severe tubular epithelial cell degeneration/necrosis, epithelial cell regeneration and dilation; and a unique urinebased metabolomic fingerprint. These metabolite changes included time and treatment-dependent increases in lactate, taurine, glucose, lactate, alanine, and citrate as well as 9 other known metabolites. As early as 3 days post dose, gentamicin induced increases in urinary albumin, clusterin, neutrophil gelatinase associated protein (NGAL) and total protein concentrations. Urinary albumin, clusterin, and NGAL showed earlier and more robust elevations than traditional kidney safety biomarkers, blood urea nitrogen and serum creatinine. Elevations in urinary kidney injury molecule 1 (KIM-1) were less reliable for detection of gentamicin nephrotoxicity in dogs based on values generated utilizing multiple first-generation, canine-specific KIM-1 immunoassays. The metabolic fingerprint was further evaluated in male and female dogs that received Compound A which induced slightly reversible renal tubular alterations characterized as degeneration/necrosis and concurrent significant increases in urinary taurine amongst other markers. These data support further investigations to demonstrate the value of urinary metabolites, albumin, clusterin, NGAL and taurine as promising markers to enable early detection of DIKI in dogs.
尿蛋白生物标志物和代谢组学标志物已被用于检测大鼠急性药物性肾损伤(DIKI);然而,这些指标在犬类模型中用于早期检测DIKI的效用尚未得到充分记录。因此,我们评估了雄性和雌性比格犬尿液中生物标志物和代谢物的时间变化。庆大霉素诱导的雄性犬肾损伤的特征为中度至重度肾小管上皮细胞变性/坏死、上皮细胞再生和扩张;以及独特的基于尿液的代谢组学指纹图谱。这些代谢物变化包括乳酸、牛磺酸、葡萄糖、乳酸、丙氨酸和柠檬酸盐以及其他9种已知代谢物随时间和治疗的增加。早在给药后3天,庆大霉素就导致尿白蛋白、簇集素、中性粒细胞明胶酶相关蛋白(NGAL)和总蛋白浓度升高。与传统的肾脏安全生物标志物血尿素氮和血清肌酐相比,尿白蛋白、簇集素和NGAL的升高更早且更显著。基于使用多种第一代犬特异性KIM-1免疫测定法产生的值,尿肾损伤分子1(KIM-1)的升高在检测犬庆大霉素肾毒性方面不太可靠。在接受化合物A的雄性和雌性犬中进一步评估了代谢指纹图谱,化合物A诱导了轻度可逆的肾小管改变,其特征为变性/坏死,同时尿牛磺酸及其他标志物显著增加。这些数据支持进一步研究,以证明尿代谢物、白蛋白、簇集素、NGAL和牛磺酸作为有望用于早期检测犬DIKI的标志物的价值。